The Scottish Medicines Consortium (SMC) has accepted Afinitor® (everolimus), for women with advanced breast cancer within NHS Scotland.
Everolimus – in combination with exemestane – is indicated for use in postmenopausal women, without symptomatic visceral organ disease, and following recurrence after use of a non-steroidal aromatise inhibitor.
Novartis had recognised an unmet need for this group of patients in Scotland and, before everolimus was accepted by the SMC, the only alternative treatment was chemotherapy.
This decision follows a swift resubmission by Novartis, to the SMC, after everolimus initially failed to get recommendation in October 2015.
Barbara McLaughlan, Head of External Affairs, Novartis Oncology UK and Ireland, said: “We’re delighted with this outcome, which reflects how the new SMC evaluation process is making a positive difference for people living with cancer in Scotland.”